biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	5/3/2018 9:58:39 AM
	Read Replies (1) of 3661

Achaogen (AKAO) off 26% on negative AdCom vote for Plazomicin in blood stream infections. AKAO hopes for approval in this indication under the Limited Population Antibiotic Drug pathway. It would be the first drug to be so approved if the FDA ignores the AdCom. It will likely be approved for cUTI, as the positive vote for that indication was unanimous. But the twittersphere claims that is unimportant. Perhaps because that narrow a label spells marketing struggle? It's still a pretty large addressable market. Anyhow, AKAO, has a pipeline. Had the carnage been worse - single digit share price - it might be worth bottom fishing. Not sure what to make of the regulatory murk here. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next